Perioperative blood transfusion has a dose-dependent relationship with disease recurrence and survival in patients with non-small cell lung cancer

被引:31
|
作者
Latif, M. Jawad [1 ]
Tan, Kay See [2 ]
Molena, Daniela [1 ]
Huang, James [1 ]
Bott, Matthew J. [1 ]
Park, Bernard J. [1 ]
Adusumilli, Prasad S. [1 ]
Rusch, Valerie W. [1 ]
Bains, Manjit S. [1 ]
Downey, Robert J. [1 ]
Jones, David R. [1 ]
Isbell, James M. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Thorac Surg Serv, 1275 York Ave, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA
来源
基金
美国国家卫生研究院;
关键词
transfusion; lung cancer; lobectomy; segmentectomy; survival; propensity-score matching; recurrence; LIMITED RESECTION; SURGERY; PROGNOSIS; LOBECTOMY; IMPACT;
D O I
10.1016/j.jtcvs.2018.12.109
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Perioperative blood transfusions have been implicated in decreased overall survival (OS) and disease-free survival (DFS) after resection for non-small cell lung cancer (NSCLC). We investigated the effects of single- and multiple-unit blood transfusions on OS, DFS, and recurrence after anatomic pulmonary resection. Methods: From January 1, 2000, to June 30, 2016, 5709 consecutive patients underwent pulmonary resection for NSCLC at our institution. Exclusion criteria were stage IIIB-IV disease, incomplete resections, ill-defined histologic subtypes, and nonanatomic wedge resections. For the 0 versus single-unit analysis, propensity scores were calculated from a logistic regression model that predicted the probability of patients receiving a single-unit transfusion. The resulting matching weights were incorporated into Cox models for OS, DFS, and cumulative incidence of recurrence, to compare no versus single-unit blood transfusion. We determined whether increasing numbers of blood transfusions influenced survival or recurrence using multivariable Cox models. Results: Approximately 10% of patients received perioperative blood transfusion (median follow-up, 7.46 years [25th-75th percentile, 3.98-11.8]). There was no difference in OS, DFS, or cumulative incidence of recurrence between patients receiving no transfusion and those receiving single-unit transfusion (P > .05). However, a dose-response relationship was observed, demonstrating worse OS (overall P < .001), DFS (overall P < .001), and recurrence (overall P = .010) with increasing units of blood transfused. Conclusions: Although a single-unit blood transfusion did not affect survival in patients undergoing resection for NSCLC, greater unit perioperative blood transfusions were associated with significantly decreased long-term outcomes in a dose-dependent manner, suggesting avoidance or minimization of transfusions could improve long-term survival after lung resection.
引用
收藏
页码:2469 / +
页数:19
相关论文
共 50 条
  • [1] The influence of blood transfusion on survival in operated non-small cell lung cancer patients
    Rzyman, W
    Dziadziuszko, R
    Skokowski, J
    Wilimski, R
    Raiter, A
    Szymanowska, A
    Jassem, J
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2003, 126 (03): : 755 - 760
  • [2] Perioperative blood transfusions and survival in patients with non-small cell lung cancer: a retrospective study
    Cata, Juan P.
    Chukka, Varun
    Wang, Hao
    Feng, Lei
    Gottumukkala, Vijaya
    Martinez, Fernando
    Vaporciyan, Ara A.
    BMC ANESTHESIOLOGY, 2013, 13
  • [3] Perioperative blood transfusions and survival in patients with non-small cell lung cancer: a retrospective study
    Juan P Cata
    Varun Chukka
    Hao Wang
    Lei Feng
    Vijaya Gottumukkala
    Fernando Martinez
    Ara A Vaporciyan
    BMC Anesthesiology, 13
  • [4] Treatment and survival in patients with postoperative recurrence of non-small cell lung cancer
    Nakajima, Ryu
    Izumi, Nobuhiro
    Takahama, Makoto
    Yamamoto, Ryoji
    Tada, Hirohito
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S857 - S857
  • [5] Predictors of perioperative quality of life and survival of patients with non-small cell lung cancer
    Fukai, Ryuta
    Nishida, Tomoki
    Hibino, Makoto
    Teshima, Shinichi
    Sugimoto, Hideyasu
    QUALITY OF LIFE RESEARCH, 2024, 33 : S164 - S165
  • [6] Volume and dose parameters for survival of non-small cell lung cancer patients
    Martel, MK
    Strawderman, M
    Hazuka, MB
    Turrisi, AT
    Fraass, BA
    Lichter, AS
    RADIOTHERAPY AND ONCOLOGY, 1997, 44 (01) : 23 - 29
  • [7] SBRT Dose and Survival in Non-Small Cell Lung Cancer
    Levy, Antonin
    Guckenberger, Matthias
    Hurkmans, Coen
    Nestle, Ursula
    Belderbos, Jose
    De Ruysscher, Dirk
    Faivre-Finn, Corinne
    Le Pechoux, Cecile
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 92 (04): : 945 - 946
  • [8] The role of the blood factors in the survival of patients with non-small cell lung cancer
    Dimakakos, E.
    Cholidou, K.
    Mpakakos, P.
    Anagnostopoulos, N.
    Gkiozos, I.
    Syrigos, N.
    Kotteas, E.
    Gerotziafas, G. T.
    THROMBOSIS RESEARCH, 2021, 200 : S43 - S43
  • [9] Impact of Interstitial Lung Disease on Survival for Patients with Non-small Cell Lung Cancer
    Miyazaki, Kunihiko
    Satoh, Hiroaki
    Kurishima, Koichi
    Nakamura, Ryota
    Ishikawa, Hiroichi
    Kagohashi, Katsunori
    Ohara, Gen
    Hizawa, Nobuyuki
    ANTICANCER RESEARCH, 2009, 29 (07) : 2671 - 2674
  • [10] Interleukin polymorphisms associated with overall survival, disease-free survival, and recurrence in non-small cell lung cancer patients
    Woods, Nicholas T.
    Monteiro, Alvaro N.
    Thompson, Zachary J.
    Amankwah, Ernest K.
    Naas, Nina
    Haura, Eric B.
    Beg, Amer A.
    Schabath, Matthew B.
    MOLECULAR CARCINOGENESIS, 2015, 54 : E172 - E184